Lacrimal gland adenoid cystic carcinoma: a rare case report
- 1Ophthalmology, University of Puerto Rico School of Medicine, San Juan, Puerto Rico
- 2Pathology and Laboratory Medicine, University of Puerto Rico, San Juan, Puerto Rico
Abstract
Lacrimal gland adenoid cystic carcinoma (LGACC) is a rare and aggressive malignancy characterized by perineural invasion, late recurrence, and high mortality. No consensus treatment guidelines exist, and management strategies range from eye-sparing excision to orbital exenteration combined with chemotherapy and radiotherapy. This report describes a 32-year-old Hispanic man with a six-year history of right orbital pressure that progressed to pain, diplopia, and lacrimation. Clinical examination revealed 20/20 visual acuity bilaterally, a palpable right upper eyelid mass, and hypoglobus with inferonasal globe displacement. Imaging identified a well-defined right lacrimal gland mass, and biopsy confirmed adenoid cystic carcinoma. Intra-arterial chemoreduction was not feasible; however, three cycles of systemic cisplatin and doxorubicin resulted in no radiographic tumor reduction. The patient subsequently underwent right orbital exenteration, followed by adjuvant radiotherapy, and remains under multidisciplinary surveillance, with no evidence of local recurrence at 34 months of follow-up. LGACC is best managed with an individualized, interdisciplinary, and multimodal approach. Given the lack of consensus guidelines and the risk of late recurrence, long-term monitoring is essential, and further research is required to establish surveillance and management strategies.
Related
- Modeling the Microenvironmental Dynamics of Adenoid Cystic Carcinoma in Lacrimal Gland with Treatment Intervention
- Long-term outcomes of globe-sparing surgery combined with adjuvant radiotherapy for lacrimal gland adenoid cystic carcinoma
- Histopathology-guided spatial transcriptomic analysis identifies an ECM-associated stromal pattern in lacrimal gland adenoid cystic carcinoma with complementary proteomic and functional analyses
- Coordinated alterations in SWI/SNF chromatin remodeling complex, mRNA splicing and mRNA methylation as hallmarks of salivary gland adenoid cystic carcinoma (SACC)
- Hormone receptor-positive adenoid cystic carcinoma of the breast with cross-modality imaging discrepancy: a case report and literature review.
BibTeX
@article{marquez2026lacrimal,
title = {{Lacrimal gland adenoid cystic carcinoma: a rare case report}},
author = {Estefania Ramírez Marquez and Maria Garcia Forestier and Maria Correa and Joseph Campbell},
journal = {Frontiers in Ophthalmology},
year = {2026},
month = oct,
doi = {10.3389/fopht.2026.1936845},
url = {https://doi.org/10.3389/fopht.2026.1936845},
note = {CC BY},
}
RIS
TY - JOUR
TI - Lacrimal gland adenoid cystic carcinoma: a rare case report
AU - Estefania Ramírez Marquez
AU - Maria Garcia Forestier
AU - Maria Correa
AU - Joseph Campbell
PY - 2026
DA - 2026/10/29
JO - Frontiers in Ophthalmology
DO - 10.3389/fopht.2026.1936845
UR - https://doi.org/10.3389/fopht.2026.1936845
AB - Lacrimal gland adenoid cystic carcinoma (LGACC) is a rare and aggressive malignancy characterized by perineural invasion, late recurrence, and high mortality. No consensus treatment guidelines exist, and management strategies range from eye-sparing excision to orbital exenteration combined with chemotherapy and radiotherapy. This report describes a 32-year-old Hispanic man with a six-year history of right orbital pressure that progressed to pain, diplopia, and lacrimation. Clinical examination revealed 20/20 visual acuity bilaterally, a palpable right upper eyelid mass, and hypoglobus with inferonasal globe displacement. Imaging identified a well-defined right lacrimal gland mass, and biopsy confirmed adenoid cystic carcinoma. Intra-arterial chemoreduction was not feasible; however, three cycles of systemic cisplatin and doxorubicin resulted in no radiographic tumor reduction. The patient subsequently underwent right orbital exenteration, followed by adjuvant radiotherapy, and remains under multidisciplinary surveillance, with no evidence of local recurrence at 34 months of follow-up. LGACC is best managed with an individualized, interdisciplinary, and multimodal approach. Given the lack of consensus guidelines and the risk of late recurrence, long-term monitoring is essential, and further research is required to establish surveillance and management strategies.
SN - 2674-0826
ER -